Patent application number | Description | Published |
20090181976 | Use of Compounds Binding to the Sigma Receptor for the Treatment of Metabolic Syndrome - The present invention refers to the use of compounds binding to the sigma receptor for the treatment of metabolic syndrome. | 07-16-2009 |
20090264457 | Combination of at least two 5HT6-Ligands - The present invention relates to a Combination of at least two 5HT6-Ligands of which one is a partial or agonist while the other is a full antagonist or an inverse agonist, a medicament comprising this comination, the use of the combiantion in the manufacture of a medicament for the treatment of memory disorders ADHD, and methods of treatment using the combination or its members. | 10-22-2009 |
20090326014 | Use of 5-ht7 receptor agonists for the treatment of pain - The present invention refers to the use of 5-HT | 12-31-2009 |
20100215771 | USE OF SODIUM CHANNEL BLOCKERS FOR THE TREATMENT OF NEUROPATHIC PAIN DEVELOPING AS A CONSEQUENCE OF CHEMOTHERAPY - The present invention refers to the use of sodium channel blockers such as tetrodotoxin or saxitoxin, its analogues/derivatives as well as their acceptable salts, for the production of a medicament for the treatment of neuropathic pain resulting from chemotherapy. | 08-26-2010 |
20110028517 | 4-METHYL-4,5-DIHYDRO-1H-PYRAZOLE-3-CARBOXAMIDE USEFUL AS A CANNABINOID CB1 NEUTRAL ANTAGONIST - The present invention relates to 4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide, and pharmaceutically acceptable salts and solvates thereof. It further concerns pharmaceutical compositions comprising this compound as active ingredient as well as processes and intermediates for preparing this compound and compositions. The referred compound is a cannabinoid CB1 neutral antagonist useful in the prophylaxis and treatment of food intake disorders. | 02-03-2011 |
20110052723 | USE OF COMPOUNDS BINDING TO THE SIGMA RECEPTOR LIGANDS FOR THE TREATMENT OF NEUROPATHIC PAIN DEVELOPING AS A CONSEQUENCE OF CHEMOTHERAPY - The present invention refers to the use of compounds binding to the sigma receptor for the treatment or prevention of neuropathic pain resulting from chemotherapy. | 03-03-2011 |
20120302568 | SIGMA LIGANDS FOR USE IN THE PREVENTION AND/OR TREATMENT OF POST-OPERATIVE PAIN - The invention refers to the use of a sigma ligand, particularly a sigma ligand of formulae (I), (II) or (III) to prevent and/or treat acute and chronic pain developed as a consequence of surgery, especially superficial and/or deep pain secondary to surgical tissue injury, and peripheral neuropathic pain, neuralgia, allodynia, causalgia, hyperalgesia, hyperesthesia, hyperpathia, neuritis or neuropathy secondary to surgical procedure. | 11-29-2012 |
20130109692 | SIGMA LIGANDS FOR THE PREVENTION AND/OR TREATMENT OF EMESIS INDUCED BY CHEMOTHERAPY OR RADIOTHERAPY | 05-02-2013 |
20130324535 | USE OF SIGMA LIGANDS IN BONE CANCER PAIN - The invention refers to the use of a sigma ligand, particularly a sigma ligand of formula (I) to prevent and/or treat pain associated to bone cancer. | 12-05-2013 |
20140107111 | USE OF SIGMA LIGANDS IN DIABETES TYPE-2 ASSOCIATED PAIN - The invention refers to the use of a sigma ligand, particularly a sigma ligand of formula (I) to prevent and/or treat type-2 diabetes-associated pain and related symptoms. | 04-17-2014 |